Decitabine inhibits the cell growth of cholangiocarcinoma in cultured cell lines and mouse xenografts

Wang,Bing; Li,Hongbo; Yang,Rui; Zhou,Shunchang; Zou,Shengquan

doi:10.3892/ol.2014.2499

Decitabine inhibits the cell growth of cholangiocarcinoma in cultured cell lines and mouse xenografts

Authors:
- Bing Wang
- Hongbo Li
- Rui Yang
- Shunchang Zhou
- Shengquan Zou
View Affiliations

Affiliations: Department of General Surgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: September 4, 2014 https://doi.org/10.3892/ol.2014.2499
Pages: 1919-1924

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Decitabine (DAC), an inhibitor of DNA methyltransferase, demonstrates antitumor activities in various types of cancer. However, its therapeutic potential for cholangiocarcinoma (CCA), one of the most aggressive gastrointestinal malignancies, remains to be explored. The present study investigated the antiproliferative effects of DAC on CCA cells in vitro and in vivo. Human CCA cell lines, TFK‑1 and QBC939, were used as models to investigate DAC on the cell growth and proliferation of CCA. Cell proliferation was evaluated by Cell Counting Kit‑8 assay combined with clonogenic survival assay. Flow cytometry, Hoechst 33342/propidium iodide staining and green fluorescent protein‑tagged MAP‑LC3 detection were applied to determine cell cycle progression, apoptosis and autophagy. Nude mice with TFK‑1 xenografts were evaluated for tumor growth following DAC treatment. DAC was observed to significantly suppress the proliferation of cultured TFK‑1 and QBC939 cells, accompanied with enhanced apoptosis, autophagy and cell cycle arrest at G2/M phase. In TFK‑1 mouse xenografts, DAC retarded the tumor growth and increased the survival of CCA tumor‑bearing mice.

View Figures

View References

1	de Groen PC, Gores GJ, LaRusso NF, Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med. 341:1368–1378. 1999.
2	Shaib Y and El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004.
3	Khan SA, Emadossadaty S, Ladep NG, et al: Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol. 56:848–854. 2012.
4	Nagino M, Ebata T, Yokoyama Y, et al: Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 258:129–140. 2013.
5	Kitiyakara T and Chapman RW: Chemoprevention and screening in primary sclerosing cholangitis. Postgrad Med J. 84:228–237. 2008.
6	Wiencke K and Boberg KM: Current consensus on the management of primary sclerosing cholangitis. Clin Res Hepatol Gastroenterol. 35:786–791. 2011.
7	Beuers U: EASL Recognition Awardee 2009: Prof. Raoul Poupon J Hepatol. 51:617–619. 2009.
8	Chapman R, Fevery J, Kalloo A, et al: Diagnosis and management of primary sclerosing cholangitis. Hepatology. 51:660–678. 2010.
9	Sano T, Shimada K, Sakamoto Y, Yamamoto J, Yamasaki S and Kosuge T: One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Ann Surg. 244:240–247. 2006.
10	Shaib YH, Davila JA, Henderson L, McGlynn KA and El-Serag HB: Endoscopic and surgical therapy for intrahepatic cholangiocarcinoma in the united states: a population-based study. J Clin Gastroenterol. 41:911–917. 2007.
11	Kozarek RA: Inflammation and carcinogenesis of the biliary tract: update on endoscopic treatment. Clin Gastroenterol Hepatol. 7(11 Suppl): S89–S94. 2009.
12	Blechacz B and Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 48:308–321. 2008.
13	Ustundag Y and Bayraktar Y: Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol. 14:6458–6466. 2008.
14	Ramacciato G, Nigri G, Bellagamba R, et al: Univariate and multivariate analysis of prognostic factors in the surgical treatment of hilar cholangiocarcinoma. Am Surg. 76:1260–1268. 2010.
15	Nuzzo G, Giuliante F, Ardito F, et al: Intrahepatic cholangiocarcinoma: prognostic factors after liver resection. Updates Surg. 62:11–19. 2010.
16	Anderson CD, Pinson CW, Berlin J and Chari RS: Diagnosis and treatment of cholangiocarcinoma. Oncologist. 9:43–57. 2004.
17	Cheung HH, Lee TL, Davis AJ, Taft DH, Rennert OM and Chan WY: Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br J Cancer. 102:419–427. 2010.
18	Jurkowska RZ, Jurkowski TP and Jeltsch A: Structure and function of mammalian DNA methyltransferases. Chembiochem. 12:206–222. 2011.
19	Oki Y, Aoki E and Issa JP: Decitabine - bedside to bench. Crit Rev Oncol Hematol. 61:140–152. 2007.
20	Griffiths EA and Gore SD: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol. 45:23–30. 2008.
21	Gravina GL, Festuccia C, Marampon F, et al: Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer. 9:3052010.
22	Damaraju VL, Mowles D, Yao S, et al: Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine. Nucleosides Nucleotides Nucleic Acids. 31:236–255. 2012.
23	Yang D, Torres CM, Bardhan K, Zimmerman M, McGaha TL and Liu K: Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. J Immunol. 188:4441–4449. 2012.
24	Schnekenburger M, Grandjenette C, Ghelfi J, et al: Sustained exposure to the DNA demethylating agent, 2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy. Biochem Pharmacol. 81:364–378. 2011.
25	Chen MY, Liao WS, Lu Z, et al: Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 117:4424–4438. 2011.
26	Yi TZ, Li J, Han X, et al: DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo. Chemotherapy. 58:19–29. 2012.